More on KNBWY
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $19.02 |
|
|||
| Open | $18.40 | ||||
| 52 Wk High | $18.64 | ||||
| 52 Wk Low | $12.59 | ||||
| Day High | $18.62 | ||||
| Day Low | $18.40 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 8,708 | ||||
- Kirin and Blackmores Team Up to Release Cognitive Function Support Supplements in Australia and New Zealand Formulated with Kirin Group’s Cognizin® Citicoline
- European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union
- Kirin Holdings Co Ltd (2503:JP) (KNBWY) PT Raised to JPY2,800 at JPMorgan
- Kura Oncology reports positive long-term cancer drug trial data
- Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
- FDA approves dosing update for CRYSVITA in adults with rare bone disease
- FDA Approves New Dosing Option for CRYSVITA® (burosumab-twza) in Adults With XLH
- Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
- CRYSVITA® Now Publicly Reimbursed for the Treatment of Adults with XLH in Four Provinces and Federal Non-Insured Health Benefits Program
- Kyowa Kirin begins phase 2 trial of ziftomenib in Japan for AML
Entities mentioned with KNBWY
- FDA | View Related Stories »
- Genzyme/Sanofi-Aventis | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- PDUFA | View Related Stories »
- AdCom | View Related Stories »
- Dividend | View Related Stories »
- Show More...
